Form 4: GeneDx Holdings Corp. CFO Kevin Feeley Reports Stock Transactions

Kevin Feeley, CFO of GeneDx Holdings Corp., reports the acquisition and disposal of Class A Common Stock and Restricted Stock Units to cover tax obligations.

Summary

• On September 16, 2024, Kevin Feeley, the Chief Financial Officer of GeneDx Holdings Corp., engaged in transactions involving the company's Class A Common Stock and Restricted Stock Units (RSUs).
• Feeley acquired 7,197 shares of Class A Common Stock through the vesting of RSUs at a price of $0.
• Simultaneously, Feeley sold 2,635 shares of Class A Common Stock at $37.59 per share to cover tax withholding obligations related to the vesting of the RSUs.
• Following these transactions, Feeley directly owns 44,472 shares of Class A Common Stock and 71,969 Restricted Stock Units.
• The RSUs vest in quarterly installments of 6.25% over a 4-year period starting March 16, 2023, contingent upon continued service to the Issuer.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are routine and related to compensation and tax obligations. There is no indication of significant concern or excitement.

Positives

• The vesting of RSUs indicates a form of compensation and alignment of the CFO's interests with the company's performance.

Negatives

• The sale of shares to cover tax obligations, while common, slightly reduces the CFO's direct holdings in the company.

Risks

• Future stock transactions by insiders could influence the market's perception of the company's stock.

Industry Context

Insider transactions are routinely monitored by investors as they can provide insights into management's perspective on the company's valuation and future prospects. This transaction is a routine 'sell to cover' to manage tax obligations.

Comparison to Industry Standards

• Sell-to-cover transactions are a common practice among executives receiving equity compensation, aligning with standard practices at companies like Illumina (ILMN) and Exact Sciences (EXAS), where executives routinely manage their equity positions for tax purposes.
• The vesting schedule of 6.25% quarterly over four years is a typical vesting arrangement, similar to equity grants at companies such as Myriad Genetics (MYGN) and Invitae (NVTA).

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they are related to executive compensation and tax obligations.

Key Dates